ClinicalTrials.Gov Identifier | Biomarker(s) | Regimen | Phase | Sample Size | Stage | Primary Endpoint | Estimated or Actual Study Period [reference] |
---|---|---|---|---|---|---|---|
NCT03853187 | PD-L1 expression | Durvalumab + Zr-89 labelled Durvalumab | II | 20 | I, II or IIIa | Safety and feasibility | September 19, 2019—April 1, 2022 |
NCT04933903 | PD-L1 expression | Ipilimumab + Nivolumab + SBRT | II | 25 | IB-IIIB (T2-3N0, T1-T3N1-2) | MPR | July 2021—January 2023 |
NCT04271384 | PD-L1 expression | SABR + Nivolumab | II | 30 | I | pCR | February 12, 2020—June 29, 2023 |
NCT02987998 | PD-L1 expression | Cisplatin + Etoposide + Pembrolizumab with concurrent radiation | I | 9 | IIIA | Toxicity | May 18, 2017—January 24, 2024 |
NCT03871153 | PD-L1 expression | Neoadjuvant chemotherapy + radiation + Durvalumab | II | 25 | III (N2) | PRR | August 2, 2019 – April 2022 |
NCT03217071 | PD-L1 expression | Pembrolizumab + SRT | II | 12 | I-IIIA | Infiltrating CD3 + T cells/ μm2 | October 4, 2017—February 28, 2022 |
NCT04465968 (DEEP_OCEAN) | PD-L1 expression | CRT + Durvalumab ± Surgery + Durvalumab | III | 84 | IIB, III | OS | September 1, 2020—August 31, 2030 |
NCT03965468 (CHESS) | PD-L1 expression | Durvalumab + Carboplatin/Paclitaxel Followed with either SBRT or surgery | II | 47 | IV | PFS | November 19, 2019—December 2021 |
NCT03237377 | PD-L1 expression | Durvalumab + radiation | II | 32 | IIIA | Safety | December 12, 2017 – September 2017 |